Multi-Receptor Agonist Research: Single, Dual and Triple Agonists

Incretin and metabolic-receptor research increasingly distinguishes peptides not by a single target but by how many receptors a molecule engages at once. Understanding that spectrum is essential to interpreting research models correctly.

The agonist spectrum

• Single-receptor agonists act primarily at one receptor — for example, GLP-1 receptor agonists. See our GLP-1 peptides overview.
• Dual agonists engage two receptors. Tirzepatide is studied as a GIP/GLP-1 dual agonist.
• Triple agonists add a third pathway. Retatrutide is described as a GLP-1/GIP/glucagon triple agonist.

Why the distinction matters in research

When a research model shows an effect, attributing that effect to a specific receptor pathway requires knowing exactly which receptors the test compound engages. A dual agonist and a triple agonist are therefore not interchangeable tools — they answer different mechanistic questions. Comparative designs that include single-, dual-, and triple-agonist arms let researchers separate the contribution of each pathway.

Documentation underpins comparison

Cross-compound comparisons are only meaningful when each material's identity is verified. That is why every comparison should start from the batch Certificate of Analysis: confirm identity and reported purity for each lot before treating two materials as the compounds they are labeled to be. Reported purity and identity are separate measurements.

TagPep supplies dual- and triple-agonist research materials, including tirzepatide and retatrutide, strictly for laboratory research use only.

For laboratory research use only. Not for human or veterinary use. Not for human consumption. Not for diagnostic or therapeutic use.